Get started
Navana Pharmaceuticals PLCNavana Pharmaceuticals PLCNavana Pharmaceuticals PLC

Navana Pharmaceuticals PLC

No trades
No trades
OverviewFinancialsCommunityTechnicalsSeasonals
Full chart
Full chart

Compare with Navana Pharmaceuticals PLC



Key stats


Market capitalization
—
Dividend yield (indicated)
1.91%
Price to earnings Ratio (TTM)
12.91
Basic EPS (TTM)
5.64 BDT
Net income (FY)
‪487.81 M‬ BDT
Revenue (FY)
‪8.84 B‬ BDT
Shares float
—
Beta (1Y)
0.94

Employees


Employees (FY)
‪4.03 K‬
Change (1Y)
+470+13.20%
Revenue / Employee (1Y)
‪2.19 M‬ BDT
Net income / Employee (1Y)
‪121.01 K‬ BDT

Profile


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Mohammad Jonaid Shafiq
Website
navanapharma.com
Headquarters
Dhaka
Founded
1986
IPO date
Oct 18, 2022
ISIN
BD0497NAVPH5
FIGI
BBG01B2D0MJ4
Identifiers
ISIN BD0497NAVPH5
CFI code
ESVUFR
Navana Pharmaceuticals Plc engages in the manufacturing, marketing, and distribution of pharmaceutical products for human and animal health products and sales of the produced items in the domestic and foreign market. It operates through the following segments: Human, Export, and Veterinary. The Human segment is involved in the marketing and selling of pharmaceutical products at home and abroad. The Veterinary segment focuses on marketing, distributing, and selling veterinary, poultry, and fisheries products. The company was founded on March 31, 1986, and is headquartered in Dhaka, Bangladesh.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

Technicals


Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently asked questions


The current price of NAVANAPHAR is 73.30 BDT — it has increased by 1.52% in the past 24 hours. Watch Navana Pharmaceuticals PLC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on DSEBD exchange Navana Pharmaceuticals PLC stocks are traded under the ticker NAVANAPHAR.
NAVANAPHAR stock has risen by 1.66% compared to the previous week, the month change is a 3.68% rise, over the last year Navana Pharmaceuticals PLC has showed a 39.62% increase.
NAVANAPHAR reached its all-time high on Nov 8, 2022 with the price of 132.00 BDT, and its all-time low was 26.40 BDT and was reached on Oct 18, 2022. View more price dynamics on NAVANAPHAR chart.
See other stocks reaching their highest and lowest prices.
NAVANAPHAR stock is 3.89% volatile and has beta coefficient of 0.94. Track Navana Pharmaceuticals PLC stock price on the chart and check out the list of the most volatile stocks — is Navana Pharmaceuticals PLC there?
Yes, you can track Navana Pharmaceuticals PLC financials in yearly and quarterly reports right on TradingView.
NAVANAPHAR net income for the last quarter is ‪130.59 M‬ BDT, while the quarter before that showed ‪179.04 M‬ BDT of net income which accounts for 0.00% change. Track more Navana Pharmaceuticals PLC financial stats to get the full picture.
Navana Pharmaceuticals PLC dividend yield was 2.78% in 2025, and payout ratio reached 30.83%. The year before the numbers were 1.56% and 37.16% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Jul 12, 2026, the company has ‪4.03 K‬ employees. See our rating of the largest employees — is Navana Pharmaceuticals PLC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Navana Pharmaceuticals PLC EBITDA is ‪1.78 B‬ BDT, and current EBITDA margin is 19.99%. See more stats in Navana Pharmaceuticals PLC financial statements.
Like other stocks, NAVANAPHAR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Navana Pharmaceuticals PLC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Navana Pharmaceuticals PLC technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Navana Pharmaceuticals PLC stock shows the buy signal. See more of Navana Pharmaceuticals PLC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.